Case report: Complete response of an anaplastic thyroid carcinoma patient with <i>NRAS</i> Q61R/<i>BRAF</i> D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody. This evidence concerns the gene BRAF and thyroid gland undifferentiated (anaplastic) carcinoma.